CR20190013A - Anticuerpos anti-c5 y métodos de uso - Google Patents
Anticuerpos anti-c5 y métodos de usoInfo
- Publication number
- CR20190013A CR20190013A CR20190013A CR20190013A CR20190013A CR 20190013 A CR20190013 A CR 20190013A CR 20190013 A CR20190013 A CR 20190013A CR 20190013 A CR20190013 A CR 20190013A CR 20190013 A CR20190013 A CR 20190013A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibody
- present
- antibodies
- provides
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La invención se refiere a anticuerpos anti-C5 y métodos para usarse. En algunas modalidades, un anticuerpo anti-C5 aislado de la presente invención se une a un epítopo dentro de la cadena beta de C5 con mayor afinidad a un pH neutro que a un pH ácido. La invención también proporciona ácidos nucleicos aislados que codifican un anticuerpo anti-C5 de la presente invención. La invención también proporciona células hospederas que comprenden un ácido nucleico de la presente invención. La invención también proporciona un método para producir un anticuerpo que comprende cultivar una célula hospedera de la presente invención a fin de producir el anticuerpo. La invención proporciona además un método para producir un anticuerpo anti-C5 que comprende inmunizar un animal contra un polipéptido que comprende el dominio MG1-MG2 de la cadena beta de C5. Los anticuerpos anti-C5 de la presente invención se pueden usar como medicamento
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016120325 | 2016-06-17 | ||
| PCT/JP2017/022253 WO2017217524A1 (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190013A true CR20190013A (es) | 2019-03-05 |
Family
ID=59969459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190013A CR20190013A (es) | 2016-06-17 | 2017-06-16 | Anticuerpos anti-c5 y métodos de uso |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3472316A4 (es) |
| JP (3) | JP6202774B1 (es) |
| KR (2) | KR101852739B1 (es) |
| CN (3) | CN115960223A (es) |
| AU (1) | AU2017285763B2 (es) |
| BR (1) | BR112018075688A2 (es) |
| CA (1) | CA3021956A1 (es) |
| CL (1) | CL2018003573A1 (es) |
| CR (1) | CR20190013A (es) |
| EA (1) | EA201990018A1 (es) |
| IL (2) | IL300611A (es) |
| MX (2) | MX2018015030A (es) |
| MY (1) | MY187848A (es) |
| PE (1) | PE20190394A1 (es) |
| PH (1) | PH12018502354A1 (es) |
| SG (2) | SG11201705584VA (es) |
| TW (4) | TW202337903A (es) |
| UA (1) | UA126561C2 (es) |
| WO (1) | WO2017217524A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| NZ602884A (en) | 2008-04-11 | 2014-08-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| KR102385507B1 (ko) | 2010-11-30 | 2022-04-12 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| AU2015365167B2 (en) | 2014-12-19 | 2021-07-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies and methods of use |
| CA3027487A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| MY187848A (en) * | 2016-06-17 | 2021-10-26 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| SG11201801024XA (en) | 2016-08-05 | 2018-05-30 | Chugai Pharmaceutical Co Ltd | Therapeutic or preventive compositions for il-8-related diseases |
| KR20200059279A (ko) * | 2017-10-04 | 2020-05-28 | 알렉시온 파마슈티칼스, 인코포레이티드 | 막증식성 사구체신염을 갖는 환자의 치료를 위한 항-c5 항체의 투여량 및 투여 |
| AU2018383751A1 (en) | 2017-12-13 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
| BR112021004141A2 (pt) * | 2018-09-06 | 2021-05-25 | The Trustees Of The University Of Pennsylvania | anticorpo dependente de ph que se liga especificamente a c5 humano, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, célula, e, animal não humano geneticamente modificado. |
| AU2020261073A1 (en) * | 2019-04-24 | 2021-12-16 | Kira Pharmaceuticals (Us) Llc | Bi-functional humanized anti-C5 antibodies and factor H fusion proteins and uses thereof |
| CN113563467A (zh) * | 2020-04-28 | 2021-10-29 | 上海普铭生物科技有限公司 | 针对人补体蛋白c5的抗体及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0230985Y2 (es) | 1985-07-08 | 1990-08-21 | ||
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| DE60143859D1 (de) | 2001-06-12 | 2011-02-24 | Ericsson Telefon Ab L M | Synchronisation in einem terrestrischen umts-funkzugriffsnetzwerk (utran) |
| BRPI0211953B8 (pt) | 2001-08-17 | 2021-05-25 | Genentech Inc | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro |
| JP4333939B2 (ja) | 2001-08-27 | 2009-09-16 | ロード・コーポレーション | トロリ線の吊架装置 |
| DE10253331A1 (de) | 2002-11-14 | 2004-06-03 | Symrise Gmbh & Co. Kg | Verwendung von trans-Pellitori als Aromastoff |
| US7267849B2 (en) | 2004-03-02 | 2007-09-11 | Nitto Denko Corporation | Compensator for liquid crystal display |
| KR20080069889A (ko) | 2007-03-20 | 2008-07-29 | (주)화도 | 폴리에틸렌 관 |
| EP2129681A2 (en) * | 2007-03-22 | 2009-12-09 | Novartis Ag | C5 antigens and uses thereof |
| EP2138531B1 (en) | 2007-04-11 | 2014-10-29 | Sekisui Chemical Co., Ltd. | Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin |
| NZ602884A (en) * | 2008-04-11 | 2014-08-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| MY159396A (en) * | 2008-08-05 | 2016-12-30 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| KR20100054403A (ko) | 2008-11-14 | 2010-05-25 | 삼성전자주식회사 | 온라인 공동 작문 장치 및 방법 |
| JP5932670B2 (ja) * | 2010-03-11 | 2016-06-08 | ライナット ニューロサイエンス コーポレイション | ｐＨ依存性の抗原結合を有する抗体 |
| TW201206466A (en) * | 2010-03-11 | 2012-02-16 | Rinat Neuroscience Corp | Antibodies with pH dependent antigen binding |
| KR20110111007A (ko) | 2010-04-02 | 2011-10-10 | 이화여자대학교 산학협력단 | Ｌ／ｄ 광학변환 및 광학분할을 위한 옥타하이드로-바이나프톨 유도체 |
| KR20110122011A (ko) | 2010-05-03 | 2011-11-09 | 황보철종 | 매장 포인트 통합 관리 시스템 및 그 방법 |
| TWI596115B (zh) * | 2012-08-13 | 2017-08-21 | 再生元醫藥公司 | 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體 |
| AU2014213147B2 (en) * | 2013-01-31 | 2019-01-17 | lmmunAbs Inc. | C5 antibody and method for preventing and treating complement-related diseases |
| CA2897334A1 (en) * | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| AU2015365167B2 (en) * | 2014-12-19 | 2021-07-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies and methods of use |
| KR102467124B1 (ko) * | 2015-12-18 | 2022-11-15 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 사용 방법 |
| MY187848A (en) * | 2016-06-17 | 2021-10-26 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
-
2017
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 TW TW112120479A patent/TW202337903A/zh unknown
- 2017-06-16 TW TW106120143A patent/TWI610941B/zh active
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/ja active Active
- 2017-06-16 TW TW111107923A patent/TWI807666B/zh active
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/zh active Pending
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/ko active IP Right Grant
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/ko active IP Right Grant
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-06-16 TW TW106141573A patent/TWI789369B/zh active
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/zh active Active
- 2017-06-16 EA EA201990018A patent/EA201990018A1/ru unknown
- 2017-06-16 UA UAA201810992A patent/UA126561C2/uk unknown
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/zh active Pending
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/es unknown
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/pt unknown
- 2017-06-16 CR CR20190013A patent/CR20190013A/es unknown
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en active Application Filing
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/es unknown
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/ja active Active
-
2018
- 2018-11-08 PH PH12018502354A patent/PH12018502354A1/en unknown
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/es unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/es unknown
- 2018-12-12 IL IL263657A patent/IL263657A/en unknown
-
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017006651A2 (es) | Anticuerpos anti-c5 | |
| CO2018007374A2 (es) | Anticuerpos anti-c5 y métodos de uso | |
| CR20190013A (es) | Anticuerpos anti-c5 y métodos de uso | |
| AR103161A1 (es) | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso | |
| AR113342A1 (es) | Anticuerpos específicos cd47 / pd-l1 | |
| PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
| GT201700162A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| CO2017000510A2 (es) | Constructos de car | |
| UY35468A (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 | |
| CO2017005842A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
| BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
| PE20151613A1 (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
| ECSP14020504A (es) | Anticuerpos contra la metaloproteinasa de la matriz 9 | |
| CL2012002328A1 (es) | Anticuerpo aislado anti-tat419 que inhibe la proliferación celular; ácido nucleico que lo codifica; célula que lo produce; método para identificar anticuerpos que unen un epítopo antigénico tat419; método para inhibir la proliferación de una célula que expresa un péptido tat419; y su uso en el tratamiento de tumores cancerígenos. | |
| BR112015023262A2 (pt) | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
| AR082518A1 (es) | Anticuerpos contra il-18r1 y usos de los mismos | |
| UY35718A (es) | Anticuerpos anti-csf-1r: métodos de expresión de los mismos. | |
| CL2020001137A1 (es) | Anticuerpos anti-apoc3 y métodos de uso de estos. | |
| AR078716A1 (es) | Anticuerpos antihepsina y metodos para su uso |